Open AccessReducing the Burden of Difficult-to-Treat Major Depressive Disorder
Author(s) -
Larry Culpepper
Publication year - 2013
Publication title -
primary care companion to cns disorders/the primary care companion for cns disorders
Language(s) - English
Resource type - Journals
eISSN - 2155-7772
pISSN - 2155-7780
DOI - 10.4088/pcc.13r01515
Subject(s) - monoamine oxidase inhibitor , depression (economics) , medicine , serotonin syndrome , anxiety , psychiatry , transdermal , atypical depression , intensive care medicine , psychology , mood , monoamine oxidase , pharmacology , biochemistry , chemistry , receptor , serotonergic , serotonin , economics , macroeconomics , enzyme
Difficult-to-treat depression (eg, depression with atypical or anxious symptoms, treatment-resistant depression, or depression with frequent recurrence) is a challenging real-world health issue. This critical review of the literature focuses on monoamine oxidase inhibitor (MAOI) therapy and difficult-to-treat forms of depression.